ClinicalTrials.Veeva

Menu

US-CT Fusion for Post Implant Dosimetry

B

British Columbia Cancer Agency

Status

Completed

Conditions

Prostate Cancer

Treatments

Diagnostic Test: transrectal ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT03692104
H17-02634

Details and patient eligibility

About

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

Full description

25 participants undergoing permanent seed prostate brachytherapy will be approached to undergo collection of prostate US images at the completion of their procedure. This will add approximately 5 minutes to the duration of their brachytherapy procedure. The US study will not entail any discomfort or risk to participants as they are still under anesthesia for the implant procedure. The institution standard of care for quality assurance will be complied with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be co-registered and analyzed in the normal fashion. In addition, the post implant US images will also be co-registered with the CT and the resulting dosimetric parameters compared.

Enrollment

25 patients

Sex

Male

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • localized prostate cancer suitable for permanent seed implant brachytherapy as either monotherapy or as a boost

Exclusion criteria

  • Unable to undergo MRI

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems